Fig. 5
From: Disulfidptosis-related LncRNAs forecast the prognosis of acute myeloid leukemia
Validation of the signature in the validation and entire set. (A, B) Distribution of the risk score (top) and survival time of each patient (down) in the validation (A) and entire set (B). (C, D) Kaplan-Meier survival analysis of OS in AML Patients in the high- and low-risk groups in the validation (C) and entire set (D). (E, F) ROC curve analysis and AUC projections for 1-, 3-, and 5-year OS in the validation (E) and entire set (F).
